| Jun 12 2026 |
Will FDA Withdraw Its Wound Care Device Rule? Stakeholders Sure Hope So… |
Epstein Becker & Green, P.C. |
| Jun 12 2026 |
FTC Announces Contempt Motion Against Dietary Supplement Provider Over Alleged Unsubstantiated Health Claims |
Hinch Newman LLP |
| Jun 12 2026 |
Tip-Pooling in Cannabis Dispensaries: Be Wary of Managers and Supervisors |
Blank Rome LLP |
| Jun 11 2026 |
FDA Updates 8-Year-Old Payor Communications Guidance |
Sheppard, Mullin, Richter & Hampton LLP |
| Jun 11 2026 |
Pending State Law: New Labor Requirements for Pharmaceutical Research, Development, and Production Facilities |
Allen Matkins Leck Gamble Mallory & Natsis LLP |
| Jun 11 2026 |
The Greatest Trick- How a Hemp “Safety” Limit Outsources American CBD, Makes Americans Less Safe |
Bradley Arant Boult Cummings LLP |
| Jun 11 2026 |
What the Supreme Court’s Latest Decision on Skinny Labeling Means for Branded Drug Manufacturers |
Womble Bond Dickinson (US) LLP |
| Jun 9 2026 |
The EU Pharma Package: What U.S. Companies Need to Know |
Barnes & Thornburg LLP |
| Jun 9 2026 |
What a Blanche AG Nomination Means for Marijuana and Psychedelics |
Bradley Arant Boult Cummings LLP |
| Jun 5 2026 |
District of Massachusetts Finds Multi-State Fraud Allegations Insufficient to Anchor Chapter 93A Claims in Massachusetts |
Greenberg Traurig, LLP |
| Jun 5 2026 |
Workplace Strategies Watercooler 2026- What the DOJ’s Medical Marijuana Reclassification Means for Employers [Podcast] |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Jun 4 2026 |
I Feel Like I’m Taking Crazy Pills: Gov. Spanberger Vetoes Adult-Use Sales Law |
Bradley Arant Boult Cummings LLP |
| Jun 4 2026 |
Hikma v. Amarin: Supreme Court Reins in Induced Infringement Claims Against Skinny Label Generic Drugs |
Barnes & Thornburg LLP |
| Jun 4 2026 |
Supreme Court Hands Generics a Unanimous Win on Skinny Labels in Hikma v. Amarin |
Polsinelli PC |
| Jun 3 2026 |
Maine Revises Drug Testing Law, Broadens Employers’ Drug Testing Options |
Jackson Lewis P.C. |
| Jun 3 2026 |
DOT Stance Firm: Medical Marijuana Does Not Excuse Positive Drug Test Results |
Jackson Lewis P.C. |
| Jun 3 2026 |
Pharmaceutical Patent Written Description and Enablement Headaches? The Federal Circuit Clarifies a Cure |
Bradley Arant Boult Cummings LLP |
| Jun 3 2026 |
This Week in 340B: May 26 – June 1, 2026 |
McDermott Will & Schulte LLP |
| Jun 2 2026 |
Ninth Circuit Vacates Order Requiring EPA to Regulate Fluoridation of Drinking Water under TSCA |
Beveridge & Diamond PC |
| Jun 2 2026 |
Massachusetts Federal Court Reinforces Chapter 93A Causation Requirement and Rejects Trade Secret Misuse Theory in Pharmaceutical Case |
Greenberg Traurig, LLP |
| Jun 2 2026 |
Call for Data Launched to Revise EU Tobacco Products Directive |
Keller and Heckman LLP |
| Jun 2 2026 |
Prop 65 Pulse: April 2026 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |
| Jun 2 2026 |
Still Grounded: Why Rescheduling Doesn’t Mean Truckers and Pilots Can Light Up |
Bradley Arant Boult Cummings LLP |
| Jun 2 2026 |
APHIS Extends Determination of Nonregulated Status to Another Pioneer Corn Variety Developed Using Genetic Engineering |
Bergeson & Campbell, P.C. |
| Jun 1 2026 |
California DPR Announces Proposed New Rule to Regulate Pesticide-Treated Seeds |
Bergeson & Campbell, P.C. |
| Jun 1 2026 |
Clinical Trial Transparency Enforcement: A Practical Guide for Sponsors and Research Sites After FDA’s April 2026 Reminders |
Foley & Lardner LLP |
| Jun 1 2026 |
Virginia’s Cannabis Crossroads: Governor Spanberger’s Veto Leaves the Adult-Use Market in Limbo |
Blank Rome LLP |
| Jun 1 2026 |
EPA Finalizes Targeted Relief from HFC Technology Transitions Rule |
Beveridge & Diamond PC |
| May 31 2026 |
New Jersey’s Appellate Court Rules on Who Can Sue for Cannabis Law Violations |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| May 29 2026 |
Appellate Court Vacates and Remands District Court Decision in TSCA Fluoride Case |
Bergeson & Campbell, P.C. |
| May 29 2026 |
Connecticut Enacts Omnibus Bill With Sweeping Changes to the Workplace |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| May 29 2026 |
OIG Warns Against Product Line Royalty Payments to Physician Consultants |
HunterMaclean |
| May 28 2026 |
FDA Warns Against “Over-Reliance” on AI Pharmaceutical Manufacturing . . . But How Much Reliance Is Too Much? |
Epstein Becker & Green, P.C. |
| May 28 2026 |
Estate Planning for Winery, Brewery, and Distillery Owners |
Varnum LLP |
| May 27 2026 |
Budding Trends Baker’s Dozen: The Impacts of Marijuana’s Rescheduling |
Bradley Arant Boult Cummings LLP |
